罗沙司他治疗较低危骨髓增生异常综合征患者贫血:一项3期研究的开放标签、剂量选择、导入期结果
MATTERHORN 3期研究开放标签剂量选择导入期纳入24例较低危MDS贫血患者,分别给予罗沙司他1.5、2.0、2.5 mg/kg每周三次口服。28周和52周时37.5%患者达输血独立,54.2%和58.3%患者红细胞输注较基线减少≥50%,据此选择2.5 mg/kg作为双盲期起始剂量。
要点
- 24例可评估患者中9例(37.5%)在28周和52周达输血独立。
- 28周和52周分别有54.2%和58.3%患者红细胞输注较基线减少≥50%。
- 口服罗沙司他每周三次耐受良好,无死亡或进展为急性髓系白血病。
核心结论
- 开放标签导入期结果显示罗沙司他每周三次口服在较低危MDS贫血中耐受良好,并据此选择2.5 mg/kg作为后续双盲研究阶段的起始剂量。
研究设计与样本
- MATTERHORN为3期随机双盲安慰剂对照研究,本报告为其开放标签、剂量选择、导入期。
- 纳入基线血清促红细胞生成素≤400 mIU/mL且红细胞输注负荷低的较低危MDS贫血患者。
- 入组患者分配至罗沙司他1.5、2.0、2.5 mg/kg三个起始剂量组,每组8例。
- 主要疗效终点为前28个治疗周内连续≥8周输血独立的患者比例;随访52周。
主要发现
- 24例接受治疗患者中9例(37.5%)在28周和52周达输血独立,其中7例达输血独立时接受2.5 mg/kg剂量。
- 28周和52周分别有54.2%和58.3%患者红细胞输注较基线减少≥50%。
- 口服罗沙司他每周三次耐受良好,无死亡或进展为急性髓系白血病。
关键数值与推荐
- 主要疗效终点:前28个治疗周内连续≥8周输血独立的患者比例。
- 次要疗效终点:8周内红细胞输注较基线减少≥50%的患者比例。
- 起始剂量选择:1.5、2.0、2.5 mg/kg每周三次口服,最终选择2.5 mg/kg用于双盲期。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anemia is the predominant cytopenia in myelodysplastic syndromes (MDS) and treatment options are limited. Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia of chronic kidney disease in the UK, EU, China, Japan, South Korea, and Chile. MATTERHORN is a phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of roxadustat in anemia of lower risk-MDS. Eligible patients had baseline serum erythropoietin ≤ 400 mIU/mL, and a low packed RBC transfusion burden. In this open-label (OL), dose-selection, lead-in phase, enrolled patients were assigned to 1 of 3 roxadustat starting doses (n = 8 each): 1.5, 2.0, and 2.5 mg/kg. The primary efficacy endpoint of the OL phase was the proportion of patients with transfusion independence (TI) for ≥ 8 consecutive weeks in the first 28 treatment weeks. A secondary efficacy endpoint was the proportion of patients with a ≥ 50% reduction in RBC transfusions over an 8-week period compared with baseline. Adverse events were monitored. Patients were followed for 52 weeks. Of the 24 treated patients, TI was achieved in 9 patients (37.5%) at 28 and 52 weeks; 7 of these patients were receiving 2.5 mg/kg dose when TI was achieved. A ≥ 50% reduction in RBC transfusions was achieved in 54.2% and 58.3% of patients at 28 and 52 weeks, respectively. Oral roxadustat dosed thrice weekly was well tolerated. There were no fatalities or progression to acute myeloid leukemia. Based on these outcomes, 2.5 mg/kg was the chosen starting roxadustat dose for the ongoing double-blind study phase.
引用
- Henry DH, Glaspy J, Harrup R, et al. Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study. Am J Hematol. 2021. PMID: 34724251. doi:10.1002/ajh.26397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。